The Q1 2026 filing reveals a SPAC in a race against time, balancing a healthy trust balance against dwindling operating liquidity. The core tension for investors lies in whether the current trust accretion and the $10.63 floor are sufficient compensation for the risk of a failed combination or a dilutive merger. While the trust is compounding value, the rising operational burn and falling interest income signal a narrowing window of efficiency.
Ultimately, the investment is a bet on management's ability to source a target before the November 2026 liquidation date. The presence of a substantial trust account mitigates total loss, but the thin operating cash suggests that any delay in finding a target could necessitate further financing or sponsor loans, potentially altering the deal dynamics for public shareholders.